Alligator Bioscience Launches FINDbind

Alligator Bioscience AB has launched FINDbind, a method for antibody optimization. FINDbind is based on Alligator Bioscience's proprietary platform of technologies for protein evolution, and is tailor-made to efficiently evolve properties of monoclonal antibodies. By this method, functional libraries of antibodies are created, from which antibodies with improved or new desirable properties are selected. FINDbind has proven to be fast, efficient and reliable and simultaneously reduce royalty-stacking. Alligator Bioscience uses its proprietary technology platform, whereof FIND is the core technology, to develop new and optimize existing therapeutic and diagnostic proteins.

For further information please contact:

Gun-Britt Fransson,

CEO

Tel: + 46 46 286 42 80

Email: guf@alligatorbioscience.com

Or visit: www.alligatorbioscience.com

Home > News & Events > News > Alligator Bioscience Launches FINDbind
Last updated: 2007-04-27

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

Alligator Bioscience AB

Alligator Bioscience AB

Alligator Bioscience AB is a biotechnology company that focuses on discovery and development of early protein drug candidates, independently and in partnership, within inflammation and cancer. Since 2001, the FIND® (Fragment INduced Diversity) technology platform has been validated by successfully...